Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

BPC-157

healingrecoverytissue-repairinflammation
Regulatory status — Research use only — not approved for human use

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — originally isolated from human gastric juice as a fragment of a larger cytoprotective protein.[3] It has no known endogenous receptor or signalling cascade of its own; instead, it appears to act as a modulator of multiple existing healing pathways simultaneously, which accounts for the unusually broad range of effects seen in preclinical studies.

The overwhelming majority of BPC-157 research has been conducted in rodent models — rats and mice — primarily by Sikiric's research group at the University of Zagreb. The peptide has been studied across an extraordinary range of conditions: tendon and ligament tears,[1] muscle injuries,[2] bone fractures, gut inflammation and ulceration,[4] colitis,[12] fistula healing,[7] peripheral nerve damage,[10] and even traumatic brain injury.[11] In nearly all these models, BPC-157 consistently accelerated healing compared to vehicle-injected controls.

Despite the absence of human trial data, BPC-157 has become one of the most widely discussed peptides in performance recovery and longevity communities. Its appeal rests on the depth of the animal literature, the apparent absence of serious adverse effects in that literature, and the theoretical alignment between its mechanisms (VEGFR2 activation, nitric oxide modulation, fibroblast recruitment) and human tissue biology.

Evidence coverage

28/47 claims verified by independent fact-checker.

9 claims pending coverage
  • Source attribution gap(4 claims)
  • Evidence tier below threshold(3 claims)
  • No inline citation in this specific bullet. FAILED: missing citation for a factual claim about the state of evidence.(1 claim)
  • FDA prescribing-label data(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
multiple
Frequency
No human clinical data establish a dosing frequency. Animal studies and preclinical reviews employ varied schedules depending on model and indication [3]; human community protocols exist but have not been clinically validated.
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • A 15-amino-acid synthetic peptide derived from human gastric juice proteins, first described in 1993.[3]
  • Plasma half-life is measured in minutes following IV injection, but the peptide demonstrates prolonged local tissue activity — likely via binding to extracellular matrix proteins at injury sites.
  • Most-studied mechanisms: VEGFR2 activation → angiogenesis;[1] nitric oxide pathway modulation;[5] growth factor receptor upregulation (EGF, FGF, FAK/paxillin).[1]
  • Research dosed at 10 µg/kg–10 mg/kg in rodents; human equivalent dose (HED) extrapolation suggests ~200–500 mcg/day for a 75 kg adult — though HED conversions are approximations.
  • Administered subcutaneously (near injury site for local effect) or intramuscularly; oral form studied specifically for gut indications.[4]
  • Evidence base: entirely preclinical (animal models). No completed, published RCTs in humans. Anecdotal human reports are numerous but uncontrolled.
  • Regulatory status: research chemical in most jurisdictions. Not approved by FDA or EMA for human therapeutic use. In 2024, FDA guidance restricted its use in compounded preparations.
  • Key theoretical safety concern: pro-angiogenic mechanism could theoretically promote growth of occult malignancies. No confirmed cases reported in the literature.[6]
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

BPC-157 acts on multiple parallel pathways — this multi-system action underlies its broad tissue repair profile.

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV, MW 1419) isolated as a partial sequence of human gastric juice protein [1]. Mechanistic and animal-model research points to several converging pathways, though none has been validated in controlled human trials. Animal studies indicate that BPC-157 upregulates vascular endothelial growth factor (VEGF) expression and angiogenic signaling in preclinical models, potentially accelerating neovascularization at sites of injury [18] [3] [12] [14]. Mechanistic data also point to modulation of the nitric oxide (NO) system: animal studies suggest BPC-157 influences nitric oxide synthase (NOS) activity and interacts with L-arginine/L-NAME pathways to regulate vascular tone, thrombosis, edema, and cytoprotection [18] [12] [11]. In vitro and animal research suggests BPC-157 enhances collagen synthesis and fibroblast activity in tendon tissue [3] [1], and in vitro evidence indicates it upregulates growth hormone receptor expression in tendon fibroblasts [15]. Animal studies further suggest modulation of vascular responses — including vasodilation, vasoconstriction, thrombosis control, and edema formation — through NO, VEGF, and focal adhesion kinase (FAK) pathways [14]. The mechanism of action remains incompletely understood; multiple pathways have been proposed across independent preclinical laboratories but have not been unified or confirmed in human studies.

What the research says

The BPC-157 literature is extensive by peptide research standards — over 100 peer-reviewed papers, primarily published in journals such as the Journal of Applied Physiology, Current Pharmaceutical Design, and European Journal of Pharmacology. However, the evidence base has structural limitations that are important to understand before drawing conclusions about human efficacy.

Musculoskeletal and Tendon Healing

The tendon healing literature is among the strongest. Chang et al. (2011) demonstrated that BPC-157 promoted tendon outgrowth, cell survival, and fibroblast migration in both in vitro and in vivo rat models, with dose-dependent VEGFR2 upregulation.[1] Pevec et al. (2010) showed that BPC-157 counteracted the impairment of muscle healing caused by systemic corticosteroid administration — a relevant finding for athletes using anti-inflammatory drugs alongside recovery protocols.[2] Gwyer et al. (2019) comprehensively reviewed the musculoskeletal data and concluded that the evidence for soft-tissue repair is mechanistically coherent and consistently positive across animal models.[6]

Gastrointestinal Effects

BPC-157's gastrointestinal healing profile is the most extensively published area of research. Sikiric et al. have demonstrated efficacy in models of gastric ulceration, colitis, fistula healing, Crohn's-like lesions, and gut-brain axis dysregulation.[3][7][12] Huang et al. (2015) confirmed pro-healing and angiogenic effects in a wound healing model, supporting the idea that BPC-157's vascular effects apply broadly across epithelial tissue types, not only gastrointestinal mucosa.[4]

Neurological and Brain-Gut Effects

Multiple papers examine BPC-157's effects on the nervous system. Vukojevic et al. (2022) reviewed central nervous system effects, including counteraction of CNS lesions, brain trauma recovery, and neurotransmitter modulation.[10] Klicek et al. (2013) showed that BPC-157 healed cysteamine-induced colitis and colon anastomoses while also counteracting cuprizone-induced brain injuries and motor disability in rats.[11]

Critical Limitations

Several significant limitations constrain the interpretation of this literature:

  • ·Single research group dominance: the vast majority of BPC-157 publications come from Sikiric's Zagreb group. Independent replication by other laboratories is limited, which is a standard criterion for scientific confidence.
  • ·Species translation uncertainty: rodent models of tissue healing do not always translate to human outcomes. Rodents heal faster and with different biology than humans in several key respects.
  • ·No published human RCTs: one Phase I trial (NCT04202874) was registered, but peer-reviewed results have not been published. No Phase II or Phase III data exists.
  • ·Dose extrapolation uncertainty: converting rodent mg/kg doses to human equivalents using body surface area scaling is an approximation, not a validated pharmacokinetic model for this compound.
100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Medical review
  • Reviewed with a licensed clinician given research-only status and absence of human efficacy trials.
  • Current medications assessed for potential NO-system or anticoagulant interactions [11] [13].
  • Awareness that no FDA, EMA, or Health Canada approval exists for any indication.
Informed consent / risk awareness
  • Understands that all human dosing is extrapolated from animal models and community protocols, not clinical trials.
  • Aware that human pharmacokinetic, long-term safety, and drug-interaction data are absent.
  • Aware that the only published human safety data involve two participants in an open-label pilot study [2].
Source and purity verification
  • Compound sourced from a supplier with verifiable third-party purity testing (HPLC, mass spectrometry).
  • Sterility confirmed for any injectable preparation.
  • Confirm there are no contraindicated medications, particularly anticoagulants or NO-system-modulating agents, given mechanistic interactions suggested in animal models [13] [11].
  • Acknowledge that no FDA-approved indication exists and that human efficacy data are absent; use is experimental.
  • Consult a qualified clinician familiar with investigational peptide use before initiating any protocol.

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • No human clinical trial protocol has been established; all in-use protocols are community-derived and lack clinical validation.
  • Monitor for any unexpected vascular, gastrointestinal, or hemostatic effects given the compound's proposed mechanisms in animal models [14] [13].
  • Document subjective and objective responses; the current literature base relies heavily on animal data and would benefit from structured observational reporting.

After — Post-cycle

  • No human data inform cycling or post-cycle protocols; community protocols exist but are not clinically validated.
  • Long-term safety of repeated BPC-157 use in humans is unknown; no studies have assessed this.

Stacks it appears in

BPC-157 + TB-500

BPC-157TB-500
Injury repair

BPC-157 drives local angiogenesis and fibroblast recruitment at the injury site; TB-500 (Thymosin Beta-4 fragment) promotes systemic actin-driven cell migration and tissue repair across a broader area. The combination is theorised to address both local and systemic healing signals for acute soft-tissue injuries.

View TB-500 page →

BPC-157 + Ipamorelin

BPC-157Ipamorelin
Recovery + GH pulse

BPC-157 addresses direct tissue repair pathways while Ipamorelin stimulates pulsatile GH release, elevating IGF-1 for systemic anabolic and repair signalling. The combination is used by those seeking both acute injury recovery and broader body composition or recovery benefits.

View Ipamorelin page →

BPC-157 + KPV

BPC-157KPV
Gut healing

KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-MSH with direct anti-inflammatory activity in gut epithelium. Combining with oral BPC-157 is anecdotally used for inflammatory bowel conditions. Both peptides have demonstrated mucosal healing activity in rodent colitis models, but no human combination data exists.

Related peptides

Other compounds indexed on Pepteligence that share research tags with BPC-157. Educational context only.

TB-500

Tier 3
healingrecoveryinflammation

Thymosin Alpha-1

Tier 3
inflammation

DSIP

Tier 2
recovery

CJC-1295

Tier 3
recovery

Safety

Common side effects

  • ·No systematic human adverse-effect data exist. The single published human pilot study (n=2, intravenous, 10–20 mg) reported no serious adverse events [2], but sample size is insufficient to characterize common side effects.

Rare side effects

  • ·[insufficient evidence in research packet — no human trial data of sufficient size]
Safety notice — Serious / theoretical risks:
  • No serious adverse events were reported in the only published human safety study (n=2) [2]; this sample size cannot exclude serious harms.
  • Animal studies suggest modulation of hemostasis and anticoagulation pathways [13]; theoretical risk of bleeding or clotting interaction in humans taking anticoagulants cannot be excluded.

Contraindications

  • ·No absolute contraindications have been established in human studies due to the absence of clinical trial data.
  • ·Use with anticoagulants (warfarin, heparin) or antiplatelet agents (aspirin) warrants caution: animal studies indicate BPC-157 modulates hemostasis and reduces bleeding time in anticoagulated rats [13]; human interaction data are absent.
  • ·Use with nitric oxide–modulating agents (nitrates, phosphodiesterase inhibitors, NOS inhibitors such as L-NAME) warrants caution: animal studies demonstrate that BPC-157 counteracts L-NAME and modulates NOS pathways [11] [12]; human pharmacokinetic interaction data do not exist.
  • ·Pregnancy, lactation, pediatric populations, and individuals with renal or hepatic impairment: no safety data available in these populations.

Community experiences (2)

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.
★★★★★Would repeat

Anonymous · 3w ago · 25-34, male

Goal: Accelerate tendon recovery after a partial tear

Significant improvement in tendon pain after week 3. By week 6 I was back to full training loads. No side effects. Would start sooner in future. Stacked with TB-500 for first 4 weeks.

250 mcg · Once daily, morning fasted · subcutaneous · for 6 weeks

Stacked with: TB-500

Also used: creatine 5g/day

★★★★★Would repeat

Anonymous · 3w ago · 25-34, male

Goal: Test full form submission flow

Significant reduction in pain after week 3. Full return to training by week 6. No side effects observed. Would use again if injured.

250 mcg · Once daily · subcutaneous · for 6 weeks

Have you tried BPC-157?

Share your protocol and outcome to help build the community dataset.

Share your experience →

BPC-157 — at a glance

PropertyBPC-157—
OriginFragment of human gastric cytoprotective proteinFragment of Thymosin Beta-4 (naturally occurring protein)
Sequence length15 amino acids (pentadecapeptide)17 amino acids (heptadecapeptide fragment)
Half-lifeMinutes (plasma); prolonged local activity~3–4 days (longer systemic activity)
RouteSC or IM injection; oral for gut useSC injection only (standard)
Typical dose200–500 mcg/day2–5 mg twice weekly (loading), 2 mg weekly (maintenance)
Primary mechanismVEGFR2 activation, FAK/paxillin, NO modulationActin regulation, cell migration, anti-inflammatory cytokines
Primary strengthLocal angiogenesis; gut healing; broad multi-system activitySystemic distribution; muscle and cardiac tissue; flexibility
Evidence strengthAnimal (extensive; 100+ studies)Animal (moderate; fewer independent replications)
Gut researchExtensive — original derivation is gastrointestinalMinimal gut-specific data
Human trialsPhase I registered (NCT04202874); results unpublishedNo registered human trials

Frequently asked questions

What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide originally derived from human gastric juice protein. It is not FDA-approved and is classified as a research compound. No controlled human clinical trials have established its safety or efficacy for any indication.
How does BPC-157 work?
Preclinical research suggests BPC-157 may act through several converging pathways, including upregulation of vascular endothelial growth factor (VEGF) expression and modulation of nitric oxide signaling. These mechanisms have been observed in animal models only — none has been validated in controlled human trials.
What is BPC-157 used for?
Animal and preclinical research has investigated BPC-157 in the context of tissue repair and healing. These findings come exclusively from animal studies. No controlled human clinical trials have established efficacy or safety for any indication.
Is BPC-157 FDA-approved?
No. BPC-157 does not hold FDA approval for any indication. It is classified as a research compound and has not completed the clinical trial process required for drug approval in the United States.
What are common dosages of BPC-157?
No human clinical dosing data exist for BPC-157. Animal studies and preclinical reviews use varied schedules depending on model and indication. Community-reported protocols exist but have not been validated in clinical trials — dosing information should be interpreted with that limitation in mind.
How is BPC-157 administered?
Based on preclinical research, BPC-157 has been studied via multiple routes including subcutaneous injection and oral administration. No route of administration has been validated for safety or efficacy in controlled human trials.
What are common side effects of BPC-157?
Because no controlled human trials have been conducted, a comprehensive side-effect profile for BPC-157 does not exist. A small pilot study examined intravenous infusion in humans, but the sample size was insufficient to characterize adverse events reliably.
Are there safety concerns with BPC-157?
Animal studies indicate BPC-157 modulates hemostasis and reduces bleeding time in anticoagulated rats, suggesting caution is warranted for people taking anticoagulants (warfarin, heparin) or antiplatelet agents. BPC-157 also appears to interact with nitric oxide pathways in animal models, so concurrent use with nitrates, phosphodiesterase inhibitors, or NOS inhibitors warrants caution. Human data on these interactions do not exist.
Can BPC-157 be combined with other peptides?
No combination protocols have been established in controlled research for BPC-157. The existing source literature does not document evidence-supported combination uses.
Is BPC-157 legal?
BPC-157 is not FDA-approved and is not a scheduled controlled substance in the United States. It occupies a regulatory grey area: it is not legal to sell for human consumption in the US. Regulatory status varies by country. This is not legal advice — consult applicable regulations in your jurisdiction.
Are there drug interactions with BPC-157?
Animal data suggest potential interactions with anticoagulants (warfarin, heparin), antiplatelet agents (aspirin), and nitric oxide–modulating compounds (nitrates, phosphodiesterase inhibitors, NOS inhibitors such as L-NAME). No human pharmacokinetic interaction data exist.
What does the research on BPC-157 show overall?
The BPC-157 research base consists almost entirely of animal and preclinical studies. No controlled human clinical trials establishing efficacy or safety have been completed. Extrapolating animal findings to human outcomes requires significant caution.

References

  1. [1]

    Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy.

    Cesarec Vedran, Becejac Tomislav, Misic Marija et al.

    European journal of pharmacology · 2013 · PMID 23220707

    View on PubMed →
  2. [2]

    Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

    Lee Edwin, Burgess Kailynd

    Alternative therapies in health and medicine · 2025 · PMID 40131143

    View on PubMed →
  3. [3]

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

    Yuan Claire, Demers Ariana, Silva-Ortiz Victor et al.

    International journal of molecular sciences · 2026 · PMID 41898733

    View on PubMed →
  4. [4]

    Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

    Gwyer Daniel, Wragg Nicholas M, Wilson Samantha L

    Cell and tissue research · 2019 · PMID 30915550

    View on PubMed →
  5. [5]

    Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine.

    Drmic Domagoj, Samara Mariam, Vidovic Tinka et al.

    World journal of gastroenterology · 2018 · PMID 30622376

    View on PubMed →
  6. [6]

    Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats.

    Lojo Nermin, Rasic Zarko, Zenko Sever Anita et al.

    PloS one · 2016 · PMID 27627764

    View on PubMed →
  7. [7]

    Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula.

    Grgic Tihomir, Grgic Dora, Drmic Domagoj et al.

    European journal of pharmacology · 2016 · PMID 26875638

    View on PubMed →
  8. [8]

    Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats.

    Baric Marko, Sever Anita Zenko, Vuletic Lovorka Batelja et al.

    Life sciences · 2016 · PMID 26872976

    View on PubMed →
  9. [9]

    Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.

    Huang Tonglie, Zhang Kuo, Sun Lijuan et al.

    Drug design, development and therapy · 2015 · PMID 25995620

    View on PubMed →
  10. [10]

    Perforating corneal injury in rat and pentadecapeptide BPC 157.

    Masnec Sanja, Kokot Antonio, Zlatar Mirna et al.

    Experimental eye research · 2015 · PMID 25912999

    View on PubMed →
  11. [11]

    Stable gastric pentadecapeptide BPC 157-NO-system relation.

    Sikiric Predrag, Seiwerth Sven, Rucman Rudolf et al.

    Current pharmaceutical design · 2014 · PMID 23755725

    View on PubMed →
  12. [12]

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.

    Sikiric Predrag, Seiwerth Sven, Skrtic Anita et al.

    Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40573323

    View on PubMed →
  13. [13]

    Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.

    Stupnisek Mirjana, Franjic Sandra, Drmic Domagoj et al.

    Thrombosis research · 2012 · PMID 21840572

    View on PubMed →
  14. [14]

    BPC 157 and blood vessels.

    Seiwerth Sven, Brcic Luka, Vuletic Lovorka Batelja et al.

    Current pharmaceutical design · 2014 · PMID 23782145

    View on PubMed →
  15. [15]

    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.

    Chang Chung-Hsun, Tsai Wen-Chung, Hsu Ya-Hui et al.

    Molecules (Basel, Switzerland) · 2014 · PMID 25415472

    View on PubMed →
  16. [16]

    BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions.

    Sikiric Predrag, Seiwerth Sven, Skrtic Anita et al.

    Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 41155565

    View on PubMed →
  17. [17]

    Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.

    Perovic Darko, Kolenc Danijela, Bilic Vide et al.

    Journal of orthopaedic surgery and research · 2019 · PMID 31266512

    View on PubMed →
  18. [18]

    Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.

    Sikiric Predrag, Barisic Ivan, Udovicic Mario et al.

    Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41901308

    View on PubMed →
  19. [?]

    Duodenocutaneous fistula in rats as a model for 'wound healing-therapy' in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine.

    Skorjanec S, Kokot A, Drmic D et al.

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2015 · PMID 26348082

    View on PubMed →
  20. [?]

    Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.

    Matek Danijel, Matek Irena, Japjec Mladen et al.

    Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41754849

    View on PubMed →
  21. [?]

    Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME.

    Djakovic Zeljko, Djakovic Ivka, Cesarec Vedran et al.

    World journal of gastroenterology · 2016 · PMID 27895400

    View on PubMed →
  22. [?]

    Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.

    Smoday Ivan Maria, Vukovic Vlasta, Oroz Katarina et al.

    Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41599787

    View on PubMed →
  23. [?]

    Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.

    Madzarac Goran, Becejac Tomislav, Penovic Toni et al.

    Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41599743

    View on PubMed →
  24. [?]

    Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.

    Sikiric Predrag, Seiwerth Sven, Skrtic Anita et al.

    Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40573261

    View on PubMed →
  25. [?]

    Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.

    Sikiric Predrag, Barisic Ivan, Udovicic Mario et al.

    Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 41754776

    View on PubMed →
  26. [?]

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.

    Grubisic Marija Medvidovic, Strbe Sanja, Barisic Ivan et al.

    Current neuropharmacology · 2026 · PMID 41832718

    View on PubMed →
  27. [?]

    Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.

    Jandric Ivan, Vrcic Hrvoje, Jandric Balen Marica et al.

    Medical science monitor basic research · 2013 · PMID 23478678

    View on PubMed →

Compare BPC-157 with…

BPC-157 vs TB-500

BPC-157 · TB-500

View comparison →